Out-Patient Billing CPT Codes

Similar documents
August 17, Dear Valued Client:

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

NeoTYPE Cancer Profiles

NeoTYPE Cancer Profiles

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

The Center for PERSONALIZED DIAGNOSTICS

Pediatric Oncology & Pathology Services

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Time Matters. Results Count! Company Overview Presentation. August Improving Patient Care through exceptional cancer genetic testing services!

Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )

TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days

molecular oncology services

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Prior Authorization Required: Additional Information:

ADRL Advanced Diagnostics Research Laboratory

Click to edit Master /tle style

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

West Midlands Regional Genetics Laboratory

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Laboratory Service Report

Overview. Methods 9/11/2017. Next Generation Sequencing and Precision Medicine in Hematological Malignancies. Genotyping in hematology

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Genetic Testing for Somatic Tumor Markers

Please Silence Your Cell Phones. Thank You

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Enhancing Assessment of Myeloid Disorders in the Era of Precision Medicine

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Precision Medicine and Molecular Testing.

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Laboratory Service Report

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

MEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17

Molecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang

Genomic Medicine: What every pathologist needs to know

Precision Oncology: Experience at UW

MOLECULAR SERVICES. mlabs.umich.edu

PROVIDER POLICIES & PROCEDURES

We are in an era that promises a rational. treatment of cancer patients. Levy et al. Genome Research 22:2201, 2012 Vanderbilt university

Accel-Amplicon Panels

Coverage Determinations Colorectal Carcinoma

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

EXT ADDRESS CITY LAST NAME ID NUMBER PT. ADDRESS CITY INSURANCE PROVIDER. 0 Other. 0 IGH/B-cell cionaliry (PCR)

Objectives and Financial Disclosure

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Next generation sequencing analysis - A UK perspective. Nicholas Lea

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Z Code Listing. Performing Site Test Code Test Description Z Code CPT Codes* IU 75950R 1p 19q FISH ZB1K BCL6 Break apart

Your single-source laboratory solution. FISH Probe Library

Z Code Listing. Performing Site Test Code Test Description Z Code CPT Codes* IU 75950R 1p 19q FISH ZB1K BCL6 Break apart

CMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.

Enhancing Assessment of Myeloid Leukemia in the Era of Precision Medicine

Enabling Personalized

Illumina s Cancer Research Portfolio and Dedicated Workflows

Diagnostica Molecolare!

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Molecular Genetic Testing for the Diagnosis of Haematological Malignancies

Session 4: Summary and Conclusions

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

The Next Generation in Cancer Diagnostics.

Transform genomic data into real-life results

Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

School of Pathology and Laboratory Medicine: Current and New Research Interests

Management of Myelodysplastic Syndromes

The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare

Current Techniques in Molecular Biology Friedel Nollet, Ph.D.

What is the status of the technologies of "precision medicine?

Molecular Diagnostics of Myeloid and Lymphoid Neoplasms

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

SUPPLEMENTARY INFORMATION

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.

Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia

Lynch Syndrome. Angie Strang, PGY2

PDX Tumor Biology Pla0orms for Drug Advancement Neal Goodwin, Ph.D. Vice President Corporate Research & Development

CLINICAL UTILITY OF INTEGRATED GENOMIC PROFILING IN PEDIATRIC LEUKEMIA

Clinical Grade Genomic Profiling: The Time Has Come

Best of ASCO 2014 Sarcoma

Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!

Diagnostic application of SNParrays to brain cancers

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Supporting Information

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Transcription:

Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB AML - No 8450 3 NeoLAB BTK Inhibitor Acquired Resistance Panel - No 8479 4 NeoLAB EGFR T790M - No 835 5 NeoLAB FLT3 Mutation Analysis - No 8479 6 NeoLAB IDH Mutation Analysis - No 80 7 NeoLAB IDH Mutation Analysis - No 8 8 NeoLAB inv(6), CBFB-MYH Translocation - No 840 9 NeoLAB KIT (c-kit) Mutation Analysis - No 87 0 NeoLAB KRAS Mutation Analysis - No 875 NeoLAB MDS/CMML - No 8450 NeoLAB Myeloid Disorders - No 8455 3 NeoLAB NPM Mutation Analysis - No 830 4 NeoLAB NRAS Mutation Analysis - No 83 5 NeoLAB PML-RARA Translocation, t(5;7) - No 835 6 NeoLAB Prostate - No 00M 7 NeoLAB RUNX-RUNXT (AML-ETO) Translocation, t(8;) - No 840 8 NeoLAB Solid Tumor Monitor - No 8479 NeoTYPE 9 NeoTYPE AML Prognostic No 8450 0 NeoTYPE AITL/Peripheral T-Cell Lymphoma No 8479 CPT Code G045 is not billed in NeoTYPE, NeoLAB Page

Out-Patient Billing CPT Codes Updated Date: August 3, 08 NeoTYPE NeoTYPE AML Favorable-Risk No 8479 NeoTYPE Brain Tumor, No 8479 3 NeoTYPE Breast Tumor No 8445 4 NeoTYPE Cervical Tumor No 8479 5 NeoTYPE CLL Prognostic No 8479 6 NeoTYPE Colorectal Tumor No 8445 7 NeoTYPE Discovery for Solid Tumors No 8455 8 NeoTYPE Endometrial Tumor No 8479 9 NeoTYPE Esophageal Tumor No 8445 30 NeoTYPE Gastric Tumor No 8445 3 NeoTYPE GI Predictive No 8479 3 NeoTYPE GIST No 8445 33 NeoTYPE Head & Neck Tumor No 8445 34 NeoTYPE JMML No 8450 35 NeoTYPE Liposarcoma Fusion No 8479 36 NeoTYPE Liver/Biliary Tumor No 8479 37 NeoTYPE Lung Tumor No 8445 38 NeoTYPE Lymphoma No 8450 39 NeoTYPE MDS/CMML No 8450 40 NeoTYPE Melanoma No 8445 4 NeoTYPE MPN No 8450 4 NeoTYPE Myeloid Disorders No 8455 43 NeoTYPE Other Solid Tumor No 8479 44 NeoTYPE Ovarian Tumor No 8445 45 NeoTYPE Pancreas Tumor No 8445 46 NeoTYPE Precision for Solid Tumors No 8445 47 NeoTYPE Soft Tissue Tumor No 8479 48 NeoTYPE Thyroid No 8445 49 BRCA Mutation & Del/Dup Analysis No 84 50 BRCA/ Mutation & Del/Dup Analysis No 86 5 Hereditary Cancer Comprehensive Panel No 843 5 Hereditary Cancer Susceptibility for Pediatrics No 8450 53 Hereditary DNA Repair Panel for Prostate Cancer No 8445 CPT Code G045 is not billed in NeoTYPE, NeoLAB Page

Out-Patient Billing CPT Codes Updated Date: August 3, 08 54 Lynch Syndrome No 8445 55 ABL Kinase Domain Mutation Analysis No 870 56 ALK Mutation Analysis No 8479 57 Androgen Receptor Mutation Analysis No 8405 58 ASXL Mutation Analysis No 875 59 ATRX Mutation Analysis No 8479 60 B-Cell Gene Rearrangement No 8479 6 BCL Translocation, t(;4) No 840 6 BCL Translocation, t(4;8) No 840 63 BCR-ABL Non-Standard p30 No 808 64 BCR-ABL Standard p0, p90 No 8479 65 BRAF Mutation Analysis No 80 66 BRCA Mutation & Del/Dup Analysis No 86 67 BTK Inhibitor Acquired Resistance Panel No 8479 68 BTK Inhibitor Primary Susceptibility Panel No 8479 69 BTK Mutation Analysis No 8406 70 CALR Mutation Analysis No 89 7 CARD Mutation Analysis No 8479 7 CBL Mutation Analysis No 8479 73 CD79B Mutation Analysis No 8479 74 CEBPA Mutation Analysis No 88 75 Chimerism/DNA Fingerprinting Analysis No 865 or 866 or 867 or 868 76 CSF3R Mutation Analysis No 8479 77 CXCR4 Mutation Analysis No 8479 78 DNMT3A Mutation Analysis No 8403 79 EGFR Mutation Analysis No 835 80 EGFR T790M Germline Mutation Analysis No 835 8 EGFRvIII Analysis No 8479 8 EPCAM Mutation & Del/Dup Analysis No 8403 83 ETV6 Mutation Analysis No 8479 84 ETV6-RUNX (TEL-AML) Translocation, t(;) No 840 85 EZH Mutation Analysis No 8479 CPT Code G045 is not billed in NeoTYPE, NeoLAB Page 3

Out-Patient Billing CPT Codes Updated Date: August 3, 08 86 FLT3 Mutation Analysis No 8479 87 GNAS Mutation Analysis No 8479 88 HOXB3 Genotyping No 8479 89 HRAS Mutation Analysis No 8403 90 HSD3B Genotyping No 8479 9 IDH & IDH Mutation Analysis No 8479 9 IgH Clonality/MRD by NGS No 863 93 IgVH Mutation Analysis No 863 94 Inherited Bone Marrow Failure Panel No 8450 95 inv(6), CBFB-MYH Translocation No 840 96 JAK Exon -4 Mutation Analysis No 97 JAK V67F Mutation Analysis No JAK Exon -4 only: 8403x. JAK V67F and Exon -4 run concurrently or by reflex: 870x, 8403x JAK V67F only: 870x. JAK V67F and Exon -4 run concurrently or by reflex: 870x, 8403x 98 KIT (c-kit) Mutation Analysis No 87 99 KRAS Exon 4 Mutation Analysis No 876 00 KRAS Mutation Analysis No 875 0 MET (c-met) Mutation Analysis No 8479 0 MET Exon 4 Deletion Analysis No 8479 03 MGMT Promoter Methylation Analysis No 887 04 Microsatellite Instability Analysis (MSI) No 830 05 MLH Mutation & Del/Dup Analysis No 894 06 MLH Promoter Methylation Analysis No 888 07 MPL Mutation Analysis No 840 08 MPN Extended Reflex Panel No 8479 09 MPN Standard Reflex Panel No 870 0 MSH Mutation & Del/Dup Analysis No 897 MSH6 Mutation & Del/Dup Analysis No 898 CPT Code G045 is not billed in NeoTYPE, NeoLAB Page 4

Out-Patient Billing CPT Codes Updated Date: August 3, 08 MYD88 Mutation Analysis No 8479 3 NGS ALK, NTRK, RET, ROS Fusion No 8479 4 NGS ALK, RET, ROS Fusion No 8479 5 NGS Comprehensive Sarcoma Fusion No 8479 6 NGS Ewing Sarcoma Fusion No 8479 7 NGS Non-Ewing Sarcoma Fusion No 8479 8 NGS Pediatric Sarcoma Fusion No 8479 9 NGS Rhabdomyosarcoma Fusion No 8479 0 NGS Thyroid Fusion No 8479 NOTCH Mutation Analysis No 8407 NPM MRD Mutation Analysis No 830 3 NPM Mutation Analysis No 830 4 NRAS Exon 4 Mutation Analysis No 8403 5 NRAS Mutation Analysis No 83 6 Oncomine Dx Target Test No 00U 7 PDGFRa Mutation Analysis No 834 8 PIK3CA Mutation Analysis No 8404 9 PLC-Gamma- Mutation Analysis No 8479 30 PML-RARA Translocation, t(5;7) No 835 3 PMS Mutation & Del/Dup Analysis No 837 3 PPMD Mutation Analysis No 8479 33 PTEN Mutation Analysis No 83 34 PTPN Mutation Analysis No 8406 35 RAS/RAF Panel No 8479 36 RHOA Mutation Analysis No 8479 37 RUNX Mutation Analysis No 8334 38 RUNX-RUNXT (AML-ETO) Translocation, t(8;) No 840 39 SETBP Mutation Analysis No 8479 40 SF3B Mutation Analysis No 8479 4 SRSF Mutation Analysis No 8479 4 STAT3 Mutation Analysis No 8405 43 T-Cell Receptor Beta Gene Rearrangement No 8340 44 T-Cell Receptor Gamma Gene Rearrangement No 834 CPT Code G045 is not billed in NeoTYPE, NeoLAB Page 5

Out-Patient Billing CPT Codes Updated Date: August 3, 08 45 TERT Promoter Mutation Analysis No 8479 46 TET Mutation Analysis No 8479 47 TP53 Mutation Analysis No 8405 48 TPMT Genotyping No 8335 49 Tumor Mutation Burden No 8479 50 UAF Mutation Analysis No 8479 5 UGTA Genotyping No 8350 5 Universal Fusion/Expression No 8450 53 WT Mutation Analysis No 8405 54 ZRSR Mutation Analysis No 8479 CPT Code G045 is not billed in NeoTYPEs, NeoLAB CPT code(s) updated - See List of tests with updated CPT Code(s) List of Tests with Updated CPT Code(s) Test No. 5 0 Test Name NeoLAB FLT3 Mutation Analysis - NeoLAB KRAS Mutation Analysis - March 08 August 08 No 845, 846 No 8479 No 875, 876 No 875 NeoTYPE Brain Tumor No 8445, G045 No 8479 3 NeoTYPE GI Predictive No 80, 8403x, 875, 876x, 83, 830, G045 No 8479 60 B-Cell Gene Rearrangement No 86, 864 No 8479 6 BCL Translocation, t(4;8) No 840 No 840 64 BCR-ABL Standard p0, p90 No 806, 807 No 8479 69 BTK Mutation Analysis No 8479 No 8406 86 FLT3 Mutation Analysis No 845 No 8479 9 IDH & IDH Mutation Analysis No 80, 8 No 8479 94 Inherited Bone Marrow Failure Panel No 8455, 8479 No 8450 00 KRAS Mutation Analysis No 875, 876 No 875 Page 6

Out-Patient Billing CPT Codes Updated Date: August 3, 08 List of Tests with Updated CPT Code(s) (Continued) Test No. Test Name March 08 August 08 08 MPN Extended Reflex Panel No 09 MPN Standard Reflex Panel No 89, 870, 840, 8403 870, 840, 8403 No 8479 No 870 3 NGS ALK, NTRK, RET, ROS Fusion No 8445 No 8479 4 NGS ALK, RET, ROS Fusion No 8404, 8479x No 8479 5 7 8 NGS Comprehensive Sarcoma Fusion NGS Non-Ewing Sarcoma Fusion NGS Pediatric Sarcoma Fusion No 8445 No 8479 No 8445 No 8479 No 8445 No 8479 0 NGS Thyroid Fusion No 8405, 8479x No 8479 35 RAS/RAF Panel No 83x, 8404x, 8405x, 8406x No 8479 37 RUNX Mutation Analysis No 840 No 8334 5 Universal Fusion/Expression No 8455 No 8450 70 Commonwealth Dr., Suite 9 Fort Myers, FL 3393 Phone: 866.776.5907/ Fax: 39.690.437 neogenomics.com 08 Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. Rev. 0838